Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 7

Results For "PIP"

767 News Found

Novartis to open Florida radioligand facility
News | January 12, 2026

Novartis to open Florida radioligand facility

New 35,000-square-foot facility in Winter Park will expand RLT manufacturing footprint to optimize delivery for patients across southeastern US


Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs
Biotech | January 11, 2026

Alveus Therapeutics launches with $159.8m Series A to advance next-gen obesity drugs

ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism


InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
Biopharma | January 11, 2026

InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway

InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development


PAI Pharma acquires Nivagen to boost US injectable drug production
News | January 11, 2026

PAI Pharma acquires Nivagen to boost US injectable drug production

The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing


Lilly to buy Ventyx Biosciences for $1.2 billion
News | January 08, 2026

Lilly to buy Ventyx Biosciences for $1.2 billion

Ventyx's clinical pipeline includes multiple small molecules with potential for oral therapies addressing chronic inflammation


Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal
Biotech | January 08, 2026

Amgen snaps up UK biotech Dark Blue Therapeutics in up to $840m oncology deal

The privately held biotech brings a first-in-class oncology program focused on small molecule–targeted protein degradation


Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity
News | January 08, 2026

Biocon Biologics to introduce three new oncology biosimilars, eyes $75 billion market opportunity

The new assets expand Biocon Biologics’ already robust oncology portfolio, which now includes 17 cancer therapies


Alumis reports breakthrough Phase 3 results for oral psoriasis therapy
Clinical Trials | January 08, 2026

Alumis reports breakthrough Phase 3 results for oral psoriasis therapy

The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data


Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs
R&D | January 06, 2026

Insilico Medicine teams up with Servier to fast-track AI-driven cancer drugs

Under the agreement, Insilico could receive up to $32 million in upfront and near-term R&D payments